example 10 [CN110740999A]   Click here for help

GtoPdb Ligand ID: 12952

Synonyms: compound 40 [PMID: 34323489] [4]
Compound class: Synthetic organic
Comment: This chemical structure was extracted from a patent claiming fourth generation EGFR inhibitors [2]. Based on a chemical structure that was submitted to the Cambridge Crystallographic Data Centre (Deposition number 2261855), and in the absence of a disclosed name-to-structure, we predict that this is likely to be the clinical lead EGFR inhibitor BBT-176 (or is closely related to it) as written about in [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 122.28
Molecular weight 601.17
XLogP 1.65
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CN1CCN(CC1)C2CCN(CC2)C3=CC=C(C(=C3)OC)NC4=NC(=C(C=N4)Cl)NC5=C(C=CC=C5)NS(=O)(=O)C
InChI InChI=1S/C28H37ClN8O3S/c1-35-14-16-37(17-15-35)20-10-12-36(13-11-20)21-8-9-25(26(18-21)40-2)32-28-30-19-22(29)27(33-28)31-23-6-4-5-7-24(23)34-41(3,38)39/h4-9,18-20,34H,10-17H2,1-3H3,(H2,30,31,32,33)
No information available.
Summary of Clinical Use Click here for help
BBT-176 has advanced to clinical evaluation for NSCLC that is resistant to earlier generation EGFR tyrosine kinase inhibitors.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04820023 Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment Phase 1/Phase 2 Interventional Bridge Biotherapeutics, Inc.